Many elderly patients with metastatic renal cell carcinoma-who are often underrepresented in clinical trials to treat the kidney cancer-are seeing overall survival benefits from treatment with targeted therapies, according to a new study from Penn Medicine researchers published this month in JAMA Network Open.